Completed
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
NCT01753076
- Conditions
- Amyotrophic Lateral Sclerosis, Central Nervous System Diseases, Metabolic Diseases, +8 more
- Locations
-
- GSK Investigational Site Boston, Massachusetts, United States
- GSK Investigational Site Grand Rapids, Michigan, United States
- GSK Investigational Site Syracuse, New York, United States
- GSK Investigational Site Columbus, Ohio, United States